References
- Callister, C. A., Le Bail, J. C., Trouilas, P., Pouget, C., Habrioux, G., Chulia, A. J. and Duroux, J. L. : Chalcones: Structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res. 21, 3949 (2001).
- Anto, R. J., Sukumara, K., Kuttan, G., Rao, M. N., Subbaraju, V. and Kuttan, R. : Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett. 97, 33 (1995). https://doi.org/10.1016/0304-3835(95)03945-S
- De Vincenzo, R., Ferlini, C., Distefano, M., Gaggini, C., Riva, A., Bombardelli, E., Morazzoni, P., Valenti, P., Belluti, F., Ranelletti, F. O., Mancuso, S. and Scambia, G. : In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother. Pharmacol. 46, 305 (2000).
- Edwards, M. L., Stemerick, D. M. and Sunkara, P. S. : Chalcones: A new class of antimitotic agents. J. Med. Chem. 33, 1948 (1990). https://doi.org/10.1021/jm00169a021
- Ko, H. H., Tsao, L. T., Yu, K. L., Liu, C. T., Wang, J. P. and Lin, C. N. : Structure-activity relationship studies on chalcone derivatives-the potent inhibition of chemical mediators release. J. Med. Chem. 46, 2813 (2003). https://doi.org/10.1021/jm030213+
- Nam, N.-H., Kim, Y., You, Y.-J., Hong, D.-H., Kim, H.-M. and Ahn, B.-Z. : Cytotoxic 2',5'-dihydroxychalcones with unexpected antiangiogenic activity. Eur. J. Med. Chem. 38, 179 (2003) https://doi.org/10.1016/S0223-5234(02)01443-5
- Rojas, J., Dominguez, J. N., Charris, J. E., Lobo, G., Pay, M. and Ferrndiz, M. L. : Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase. Eur. J. Med. Chem. 37, 699 (2002). https://doi.org/10.1016/j.ejmech.2004.09.006
- Won, S. J., Liu, C.T., Tsao, L. T., Weng, J. R., Ko, H. H., Wang, J. P. and Lin, C. N. : Synthetic chalcones as potential antiinflammatory and cancer chemopreventive agents. Eur. J. Med. Chem. 40, 103 (2005). https://doi.org/10.1016/j.ejmech.2004.09.006
- Sabzevari, O., Galati, G., Moridani, M. Y., Siraki, A. and O'Brien, P. J. : Molecular cytotoxic mechanisms of anticancer hydroxychalcones. Chem. Biol. Interact. 148, 57 (2004). https://doi.org/10.1016/j.cbi.2004.04.004
- Jin, F., Jin, X. Y., Jin, Y. L., Sohn, D. W., Kim, S.-A., Sohn, D. H., Kim, Y. C. and Kim, H. S. : Structural requirements of 2',4',6'- tris(methoxymethoxy)chalcone derivatives for anti-inflammatory activity: The importance of a 2'-hydroxy moiety. Arch. Pharm. Res. 30, 1359 (2007). https://doi.org/10.1007/BF02977357
- Lee, S. H., Seo, G. S., Kim, H. S., Woo, S. W., Ko, G. and Sohn, D. H. : 2',4',6'-Tri(methoxymethoxy)chalcone attenuates hepatic stellate cell proliferation by a heme oxygenasedependent pathway. Biochem. Pharmacol. 72, 1322 (2006). https://doi.org/10.1016/j.bcp.2006.08.004
- Lee, S. H., Seo, G. S., Kim, J. Y., Jin, X. Y., Kim, H. D. and Sohn, D. H. : Heme oxygenase-1 mediates anti-inflammatory effects of 2',4',6'-tris(methoxymethoxy) chalcone. Eur. J. Pharmacol. 532, 178 (2006). https://doi.org/10.1016/j.ejphar.2006.01.005
- Jin, F., Jin, X. Y., Jin, Y. L., Sohn, D. W., Kim, S.-A., Sohn, D. H., Kim, Y. C. and Kim, H. S. : Structural requirements of 2',4',6'- tris(methoxymethoxy)chalcone derivatives for anti-inflammatory activity: The importance of a 2'-hydroxy moiety. Arch. Pharm. Res. 30, 1359 (2007). https://doi.org/10.1007/BF02977357
- Jin, Y. L., Jin, X. Y., Jin, F., Sohn, D. H. and Kim, H. S. : Structure activity relationship studies of anti-inflammatory TMMC derivatives: 4-dimethylamino group on the B ring responsible for lowering the potency. Arch. Pharm. Res. 31, 1145 (2008). https://doi.org/10.1007/s12272-001-1281-7